Displaying drugs 7951 - 7975 of 8040 in total
Avdoralimab
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Investigational
Caldaret
Investigational
Tezacitabine
A synthetic purine nucleoside analogue with potential antineoplastic activity.
Investigational
Labetuzumab
Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Investigational
Archexin
Investigational
Tipapkinogene sovacivec
Investigational
LGD-1550
LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Investigational
DOTMP HO-166
DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy...
Investigational
MAS825
Investigational
Oregovomab
Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Investigational
4-O-Demethylpenclomedine
Investigational
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Meplazumab
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Investigational
Fiboflapon
Investigational
Lucatumumab
Investigational
Tucidinostat
Investigational
CX516
Investigational
BNC105
Investigational
Endostatin
Investigational
Pegdinetanib
CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis pathway. As a result, CT-322 blocks all known ligands for VEGFR-2.
Investigational
Recombinant Bacterial ACE2 Receptors-like Enzyme
B38-CAP is structured as a carboxypeptidase and derived from Paenibacillus sp. The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Investigational
Dihydroquinidine barbiturate
Experimental
Tridolgosir
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Experimental
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
Displaying drugs 7951 - 7975 of 8040 in total